Category
6 articles
Many U.S. emergency departments rely on limited urine immunoassay panels that omit barbiturates or return misleading negatives. The result can delay recognition of toxicity and withdrawal risk, especially when clinical decision support is silent. This ethics and patient-safety review maps the testing gap and proposes targeted assays plus better diagnostic prompts.
Barbiturate withdrawal remains a clinical orphan in many U.S. detox units and emergency departments, where intake tools built for opioids and alcohol can miss the risk of seizures, delirium, and death. This article outlines a harm-reduction protocol that treats screening, tapering, monitoring, and discharge planning as one continuous safety process.
Death certificates are legal documents, not epidemiologic instruments, and barbiturate mortality data inherit that limitation. Better toxicology reporting and coding could make hidden risk visible without turning grief into paperwork.
Palliative sedation, terminal extubation, and deliberate lethal dosing are not the same act, yet policy and media often fold them into one phrase. This ethics analysis argues that clearer terminology is a safeguard for patients, clinicians, and regulators.
Package inserts and poison center protocols are often treated as neutral sources of clarity, but they are built for regulatory review and triage, not individualized lethality counseling. For barbiturates, that distinction matters more than clinicians may realize.
Members of the public increasingly ask lethal-dose questions in forums, comment sections, and search-driven encounters, and clinicians are being drawn into answering them. This policy piece maps the competing duties at stake and proposes a triage framework and institutional guidance for US health systems and professional bodies in 2026.